Amylin Pharmaceuticals, Inc. (AMLN) Posts Q3 Loss of $0.07, Sales Fall Short
Tweet Send to a FriendGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
EPS Growth %: +4.2%
Financial Fact:
Collaborative profit sharing: 0
Today's EPS Names:
MGT, RXN, KID, More
EPS Growth %: +4.2%
Financial Fact:
Collaborative profit sharing: 0
Today's EPS Names:
MGT, RXN, KID, More
Trade AMLN Now!
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q3 EPS of ($0.07), $0.08 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $155.1 million versus the consensus estimate of $166.39 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Best Buy (BBY) Posts Q1 adj.-EPS of 32c; Comps Down 1.1%
- Vodafone (VOD) Reports Mixed FY13 Results; Will Retain Verizon Wireless Dividend
- Monro Muffler, Inc. (MNRO) Reports In-Line Q4 EPS; Guides Q1, FY14
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
